Henry Ford Hospital Medical Journal


We have studied 39 patients doubly heterozygous for sickle cell/β-thalassemia, 12 with sickle cell/βo- thalassemia and 27 with sickle cell/β+-thalassemia. Generally, sickle cell/βo-thalassemia is considered more severe than sickle cell/β+-thalassemia. In our study, however clinical complications in the group with sickle cell/β+-thalassemia were seen almost as frequently as in the group with sickle cell/βo-thalassemia. A wide variety of clinical manifestations were seen in both groups of patients.